Improve The Quality Of Life Of Older Cancer Patients
HORIZON Research and Innovation Actions
Basic Information
- Identifier
- HORIZON-MISS-2026-02-CANCER-07
- Programme
- Supporting the implementation of the Cancer Mission
- Programme Period
- 2021 - 2027
- Status
- Forthcoming (31094501)
- Opening Date
- February 10, 2026
- Deadline
- September 15, 2026
- Deadline Model
- single-stage
- Budget
- €15,000,000
- Min Grant Amount
- €5,000,000
- Max Grant Amount
- €5,000,000
- Expected Number of Grants
- 3
- Keywords
- HORIZON-MISS-2026-02-CANCER-07HORIZON-MISS-2026-02Comparative effectiveness researchHomecareIntegrated careMechanisms of painMental healthPatient care
Description
Proposals under this topic should aim to deliver results that are directed and tailored towards and contribute to the following expected outcomes:
- Improved understanding of care needs of older patients with cancer and approaches to address them;
- Older cancer patients gain access to innovative age-specific approaches and tools better tailored to their care needs;
- National healthcare providers, policymakers and authorities in European regions, EU Member States and Associated Countries have the evidence to implement tailored care for older cancer patients that have the potential to be implemented in routine treatment and follow-up care in their healthcare systems;
This topic contributes to the EU Cancer Mission’s objective to improve quality of life of cancer patients. The focus is on cancer patients aged 65 years and above.
Currently, older cancer patients represent the largest proportion of cancer patients especially in Europe, with more than two thirds of new cancer cases being diagnosed in patients above the age of 65. Yet, there is still relatively little knowledge about their functional health and care needs during and after treatment.
Managing cancer in older patients is complex, due to the high heterogeneity in terms of their intrinsic health capacities, including mental health and cognitive capacities, comorbidities, frailty etc. as well as with regard to their performance activities including social interactions, work, mobility etc. Consequently, overall health care needs of older patients with cancer vary significantly.
Older cancer patients are consistently underrepresented in clinical research, with representation declining progressively with increasing age. This leads to a lack of knowledge regarding treatments, specific needs, and clinical endpoints. Older patients are also particularly vulnerable to treatment toxicities loss of muscle mass, and may experience a large variety of confounding comorbidities and symptoms, which strongly impact their quality of life during and after treatment.
As such, quality of life expectations should be systematically factored in the decision process to define the optimal approach to cancer management.
The overall goal of this topic is to advance the understanding of older cancer patients' care needs, and develop innovative, age-sensitive care approaches and tools to boost overall quality of life. In particular:
- Building on data from existing or newly established cohorts provide a thorough assessment of QoL needs and relevant dimensions in older patients, taking into account aspects such as social and health determinants, including sex, gender, age, comorbidities, intrinsic and functional health status, socio-economic status, living in rural or remote areas, education, access/reachability to disease management programs (due to travel distances and abilities) etc.
- Develop, test, implement and scale up innovative, holistic approaches and tools in real-life settings (e.g. through the implementation of pragmatic clinical trials or effectiveness-implementation hybrid designs) to optimize treatment and/or follow-up regimens for older patients, aiming to reduce comorbidities, impairments and frailty, while improving overall quality of life. Prehabilitation strategies (e.g. to be delivered after diagnosis but prior to treatment) should be also considered. The development of these approaches and tools should consider the potential gender-related differences in treatment outcomes and quality of life, such as the impact of hormonal changes, or caregiving responsibilities.
- Primary and secondary endpoints of the pragmatic clinical trial(s) should support patient-reported outcomes and quality of life. Such endpoints should be defined together with patients and their caregivers through research that stimulates social innovation and supports end-user engagement using participative research models.
- Particular attention should be given to aspects such as pain management, cognitive and social support, mental health services etc. Additionally, rehabilitation tackling common concerns such as reduced mobility, osteoporosis, cardiovascular health, neurocognitive changes, sleep disturbance, loss of independence, time and financial toxicity etc, essential for maintaining good quality of life, should also be addressed. Health literacy including digital literacy could also be considered. The specific needs of families and care givers managing older cancer patients should also be considered.
- Ultimately, provide scientific evidence to deliver affordable and accessible treatment and follow-up care adapted to the needs of older cancer patients and to the specificities of the provision of care at local, regional, or national level, duly reflecting the (cultural) diversity across EU Member States and Associated Countries.
- All datasets produced should be described with metadata records in the EU dataset catalogue of the European Health Data Space, while all tools and models should take advantage of current European research infrastructures, should follow the principles of open science and made available through the future UNCAN.eu platform.
The topic is designed to fill a gap in terms of evidence, knowledge, expertise, tools, data and resources in the management of older cancer patients. This should be achieved through multinational, cross-sectoral and multidisciplinary cooperation.
For that purpose, projects should include an appropriate mix of stakeholders from various disciplines and sectors, including but not limited to physicians, psychologists, nurses, academia, patients and their caregivers, patient representatives, behavioural scientists, SMEs, insurance companies, charities and foundations, research organisations, civil society, regional and national health authorities
In particular, direct involvement of cancer patients and survivors, survivor representative organisations, and caregivers is required, along with effective contribution of SSH disciplines and the involvement of SSH experts, institutions as well as the inclusion of relevant SSH expertise, in order to produce meaningful and significant results, enhancing the impact of the related research activities.
Successful proposals will be asked to join the 'Quality of life” cluster for the EU Cancer Mission[1] and should include a budget for networking, attendance at meetings, and joint activities[2]. The Commission will facilitate coordination of these activities.
Applicants should provide details of the clinical studies in the dedicated annex using the template provided in the submission system.
[1] In order to address the objectives of the EU Cancer Mission, participants will collaborate in project clusters to leverage EU-funding, increase networking across sectors and disciplines, and establish a portfolio of EU Cancer Mission R&I and policy actions.
[2] Examples of these activities are research or research capacity, organising joint workshops, establishing best practices, joint communication or citizen engagement activities with projects funded under other clusters and pillars of Horizon Europe, or other EU programmes, as appropriate. Proposals are not required to include details of these activities, as they will be defined during the grant agreement preparation phase and during the life of the project
Eligibility & Conditions
General conditions
1. Admissibility Conditions: Proposal page limit and layout
2. Eligible Countries
described in Annex B of the Work Programme General Annexes.
A number of non-EU/non-Associated Countries that are not automatically eligible for funding have made specific provisions for making funding available for their participants in Horizon Europe projects. See the information in the Horizon Europe Programme Guide.
3. Other Eligible Conditions
described in Annex B of the Work Programme General Annexes.
4. Financial and operational capacity and exclusion
described in Annex C of the Work Programme General Annexes.
5a. Evaluation and award: Award criteria, scoring and thresholds
are described in Annex D of the Work Programme General Annexes.
5b. Evaluation and award: Submission and evaluation processes
The thresholds for each criterion will be 4 (Excellence), 4 (Impact) and 4 (Implementation). The cumulative threshold is 12.
are described in Annex F of the Work Programme General Annexes and the Online Manual.
5c. Evaluation and award: Indicative timeline for evaluation and grant agreement
described in Annex F of the Work Programme General Annexes.
6. Legal and financial set-up of the grants
The granting authority may, up to 4 years after the end of the action, object to a transfer of ownership or to the exclusive licensing of results, as set out in the specific provision of Annex 5.
described in Annex G of the Work Programme General Annexes.
Specific conditions
described in the [specific topic of the Work Programme]
Application and evaluation forms and model grant agreement (MGA):
Application form templates — the application form specific to this call is available in the Submission System
Standard application form (HE RIA, IA)
Evaluation form templates — will be used with the necessary adaptations
Standard evaluation form (HE RIA, IA)
Guidance
Model Grant Agreements (MGA)
Call-specific instructions
Additional documents:
HE Main Work Programme 2026-2027 – 1. General Introduction
HE Main Work Programme 2026-2027 – 12. Missions
HE Main Work Programme 2026-2027 – 15. General Annexes
HE Framework Programme 2021/695
HE Specific Programme Decision 2021/764
EU Financial Regulation 2024/2509
Decision authorising the use of lump sum contributions under the Horizon Europe Programme
Rules for Legal Entity Validation, LEAR Appointment and Financial Capacity Assessment
EU Grants AGA — Annotated Model Grant Agreement
Funding & Tenders Portal Online Manual
Frequently Asked Questions About Improve The Quality Of Life Of Older Cancer Patients
Support & Resources
Online Manual is your guide on the procedures from proposal submission to managing your grant.
Horizon Europe Programme Guide contains the detailed guidance to the structure, budget and political priorities of Horizon Europe.
Funding & Tenders Portal FAQ – find the answers to most frequently asked questions on submission of proposals, evaluation and grant management.
Research Enquiry Service – ask questions about any aspect of European research in general and the EU Research Framework Programmes in particular.
National Contact Points (NCPs) – get guidance, practical information and assistance on participation in Horizon Europe. There are also NCPs in many non-EU and non-associated countries (‘third-countries’).
Enterprise Europe Network – contact your EEN national contact for advice to businesses with special focus on SMEs. The support includes guidance on the EU research funding.
IT Helpdesk – contact the Funding & Tenders Portal IT helpdesk for questions such as forgotten passwords, access rights and roles, technical aspects of submission of proposals, etc.
European IPR Helpdesk assists you on intellectual property issues.
CEN-CENELEC Research Helpdesk and ETSI Research Helpdesk – the European Standards Organisations advise you how to tackle standardisation in your project proposal.
The European Charter for Researchers and the Code of Conduct for their recruitment – consult the general principles and requirements specifying the roles, responsibilities and entitlements of researchers, employers and funders of researchers.
Partner Search help you find a partner organisation for your proposal.
Latest Updates
No updates available.